In vivo prophylactic activity of QR-435 against H3N2 influenza virus infection

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 462-468

  Oxford, John S ^a   Lambkin, Robert ^a   Guralnik, Mario ^b,d   Rosenbloom, Richard A ^c   Petteruti, Michael P ^c   DiGian, Kelly ^b   LeFante, Carolyn ^b  

^a Retroscreen Virology Ltd   (United Kingdom)

^b Synergy Research Inc   (United States)

^c Quigley Pharma   (United States)

^d NONE   (United States)

Author keywords

Ferret; H3N2; Influenza; Oseltamivir; Prophylaxis; QR 435

Indexed keywords

GREEN TEA EXTRACT; OSELTAMIVIR; PHOSPHATE BUFFERED SALINE; QR 435; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG FORMULATION; DRUG MECHANISM; FERRET; FEVER; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VIRUS SHEDDING; VIRUS TRANSMISSION; WEIGHT REDUCTION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; ARMORACIA; DISEASE MODELS, ANIMAL; FERRETS; FEVER; INFECTION CONTROL; INFLUENZA A VIRUS, H3N2 SUBTYPE; MOTOR ACTIVITY; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; PLANT EXTRACTS; TEA; VIRUS SHEDDING; WEIGHT LOSS;

EID: 34748925844     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3180a7206e     Document Type: Article

References (39)

1. Capua I, Alexander DJ. Avian influenza and human health. Acta Trop. 2002;83:1-6.
2. Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12:9-14.
3. Sandhu SK, Mossad SB. Influenza in the older adult. Indications for the use of vaccine and antiviral therapy. Geriatrics. 2001;56:43-44,47-48,51.
4. Chow A, Ma S, Ling AE, et al. Influenza-associated deaths in tropical Singapore. Emerg Infect Dis. 2006;12:114-121.
5. Williams JR, Chen PY, Cho CT, et al. Influenza: prospect for prevention and control. Kaohsiung J Med Sci. 2002;18:421-434.
6. Cooper BS, Pitman RJ, Edmunds WJ, et al. Delaying the international spread of pandemic influenza. PLoS Med. 2006;3:e212.
7. Fleming DM. Influenza diagnosis and treatment: a view from clinical practice. Philos Trans R Soc Lond B Biol Sci. 2001;356:1933-1943.
8. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159-1169.
9. Lee C-W, Suarez DL. Avian influenza virus: prospects for prevention and control by vaccination. Anim Health Res Rev. 2005;6:1-15.
10. McGeer AJ, Lee W, Loeb M, et al. Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults. Infect Control Hosp Epidemiol. 2004;25:955-961.
11. Lynd LD, Goeree R, O'Brien BJ. Antiviral agents for influenza: a comparison of cost-effectiveness data. Pharmacoeconomics. 2005;23:1083-1106.
12. McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4:107-116.
13. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-765.
14. Lau TF, Leung PC, Wong EL, et al. Using herbal medicine as a means of prevention experience during the SARS crisis. Am J Chin Med. 2005;33:345-356.
15. Lau JTF, Leung PC, Wong EL, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. J Altern Complement Med. 2005;11:49-55.
16. Imanishi N, Tuji Y, Katada Y, et al. Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells. Microbiol Immunol. 2002;46:491-494.
17. Boyd MR, Beeson MF. Animal models for evaluation of compounds against influenza viruses. J Antimicrob Chemother. 1975;1:43-47.
18. Chen KS, Bharaj SS, King EC. Induction and relief of nasal congestion in ferrets infected with influenza. Int J Exp Pathol. 1995;76:55-64.
19. Scheiblauer H, Kendal AP, Rott R. Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species. Arch Virol. 1995;140:341-348.
20. Sweet C, Smith H. Pathogenicity of influenza virus. Microbiol Rev. 1980;44:303-330.
21. Toms GL, Davies JA, Woodward CG, et al. The relation of pyrexia and nasal inflammatory response to virus levels in nasal washings of ferrets infected with influenza viruses of differing virulence. Br J Exp Pathol. 1977;58:444-458.
22. Webster RG, Fynan EF, Santoro JC, et al. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. Vaccine. 1994;12:1495-1498.
23. Fenton RJ, Clark A, Potter CW. Immunity to influenza in ferrets. XIV: comparative immunity following infection or immunization with live or inactivated vaccine. Br J Exp Pathol. 1981;62:297-307.
24. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 2002;55:307-317.
25. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res. 2002;54:79-88.
26. Lambkin R, Oxford JS, Bossuyt S, et al. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine. 2004;22:4390-4396.
27. Mann A, Marriott AC, Balasingam S, et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to infection. Vaccine. 2006;24:4290-4296.
28. Herlocher ML, Elias S, Truscon R, et al. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis. 2001;184:542-546.
29. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002;54:99-111.
30. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001;27:37-40.
31. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-754.
32. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246.
33. Balentine DA, Wiseman SA, Bouwens LC. The chemistry of tea flavonoids. Crit Rev Food Sci Nutr. 1997;37:693-704.
34. Song J-M, Lee K-H, Seong B-L. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005;68:66-74.
35. Cheng HY, Lin CC, Lin TC. Antiviral properties of prodelphinidin B-2 3′-O-gallate from green tea leaf. Antivir Chem Chemother. 2002;13:223-229.
36. Esanu V, Prahoveanu E. The effect of an aqueous horse-radish extract, applied as such or in association with caffeine, on experimental influenza in mice. Virologie. 1985;36:95-98.
37. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J. 2001;17:1282-1293.
38. Fock R, Bergmann H, Bussmann H, et al. Conceptional considerations for a German influenza pandemic preparedness plan. Med Microbiol Immunol (Berl). 2002;191:191-195.
39. Yuen KY, Wong SS. Human infection by avian influenza A H5N1. Hong Kong Med J. 2005;11:189-199.